KBC Group NV increased its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 415,848 shares of the biopharmaceutical company’s stock after purchasing an additional 15,465 shares during the period. KBC Group NV’s holdings in Bristol-Myers Squibb were worth $21,615,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Winslow Capital Management LLC acquired a new stake in Bristol-Myers Squibb in the third quarter valued at approximately $378,839,000. Jennison Associates LLC boosted its stake in Bristol-Myers Squibb by 23.4% in the third quarter. Jennison Associates LLC now owns 21,526,559 shares of the biopharmaceutical company’s stock valued at $1,336,369,000 after acquiring an additional 4,080,245 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Bristol-Myers Squibb by 44.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 9,460,148 shares of the biopharmaceutical company’s stock valued at $587,287,000 after acquiring an additional 2,903,920 shares in the last quarter. BlackRock Inc. boosted its stake in Bristol-Myers Squibb by 2.4% in the third quarter. BlackRock Inc. now owns 114,573,885 shares of the biopharmaceutical company’s stock valued at $7,112,747,000 after acquiring an additional 2,660,326 shares in the last quarter. Finally, FIL Ltd boosted its stake in Bristol-Myers Squibb by 1,510.7% in the third quarter. FIL Ltd now owns 2,561,604 shares of the biopharmaceutical company’s stock valued at $159,023,000 after acquiring an additional 2,402,567 shares in the last quarter. Hedge funds and other institutional investors own 73.19% of the company’s stock.
Shares of Bristol-Myers Squibb stock opened at $49.71 on Wednesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.40. Bristol-Myers Squibb Co has a 1 year low of $44.30 and a 1 year high of $70.05. The firm has a market cap of $81.97 billion, a P/E ratio of 12.49, a price-to-earnings-growth ratio of 1.60 and a beta of 0.83.
The company also recently disclosed a quarterly dividend, which was paid on Friday, February 1st. Shareholders of record on Friday, January 4th were issued a $0.41 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend was Thursday, January 3rd. This represents a $1.64 dividend on an annualized basis and a yield of 3.30%. Bristol-Myers Squibb’s payout ratio is presently 41.21%.
Several equities research analysts have recently commented on BMY shares. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. BMO Capital Markets lifted their price objective on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock a “market perform” rating in a research note on Friday, November 16th. Societe Generale set a $47.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Wednesday, November 14th. Credit Suisse Group set a $59.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, February 4th. Finally, ValuEngine downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Friday, January 4th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $60.21.
TRADEMARK VIOLATION WARNING: This piece was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.com-unik.info/2019/02/13/kbc-group-nv-acquires-15465-shares-of-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Recommended Story: How prevalent are 12b-1 fees?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.